

## Institutional Biosafety Committee - Regular Meeting

Thursday, December 04, 2025

Zoom

## Meeting Minutes

VOTING MEMBERS PRESENT:	G. Babcock, K. Burns, J. Corcoran, G. Dean, M. Espinola, S. Kasper, R. Larson, E. Otten, E. Serafin, T. Rausch, F. Schaefer
VOTING MEMBERS NOT PRESENT:	S. Apewokin, D. Elsaesser, J. Yu
AD HOC MEMBERS/CONSULTANTS/GUESTS:	A. Anukanth, T. Gulley, A. Perry, J. Strasser
IBC STAFF:	D. Healy, B. Kesavalu

K. Burns convened the meeting at 12:00 p.m.

- I. **Conflicts of Interest** - No conflicts were identified.
- II. **Minutes** - Minutes from the previous IBC meeting (11/06/25) were approved (10: YES/0: NO/0: Abstained)
- III. **Old Business** - No old business was discussed
- IV. **New Business**
  - A. **Primary Protocols** (2 protocols)

*S.Kasper joined the meeting at 12:07 p.m.*

IBC Protocol Number	PI	Type of Submission	IBC Items			
1. 25-11-04-01	Latif	New Clinical	CAR-T cells			
IBC Requests:	<u>IBC Form</u> <ol style="list-style-type: none"> <li>1. <b>Section I. A</b> - Provide the UC mail code;</li> <li>2. <b>Section I. B</b> - Provide BBP transcripts for clinical staff;</li> <li>3. <b>Section II. B</b> - Rework abstract removing "informed-consent language" (second-person pronoun: you);</li> <li>4. <b>Section II. C. 1 - Gene Name</b> - In the field referring to attachment, add that document can be found in Section II. A;</li> <li>5. <b>Section II. C. 4</b> - For clarity, in "Additional Information", state that vector is not directly administered into patients. Instead, patients will receive virally transduced cells;</li> <li>6. <b>Section III. A - Location #2</b> - Provide the room number at BCHC</li> </ol>					
Motion	Approve upon modifications addressing outlined issues.					
Voting Result & Dual Use	YES: 10 <i>One member did not vote</i>	NO: 0	Abstained: 0	Dual Use? No		

IBC Protocol Number	PI	Type of Submission	Biosafety Level	IBC Items
2. 25-11-03-01	Miller-Handley	New	BSL2	<b><i>in vitro:</i></b> HDM (blood, kidney tissue/biopsy, urine) <b><i>in vitro</i></b> and <b><i>in vivo:</i></b> <i>Listeria monocytogenes</i> and Influenza virus (PR8)

<b>IBC Requests:</b>	<p><b>Main Form – General Safety:</b></p> <ol style="list-style-type: none"> <li>1. <b>Section I. D</b> - Confirm which room(s) have a biosafety cabinet (BSC);</li> <li>2. <b>Section II. B</b> - Provide more rationale/detail about how the infectious agents (<i>L. monocytogenes</i>, influenza virus) are used in this research;</li> <li>3. <b>Section III. A</b> - If the homogenizer will be used in a BSC (or chemical fume hood) for potentially infectious materials, include relevant information;</li> <li>4. <b>Section III. B</b> - Check YES for "Additional Information" and list the types of sharps that are disposed of in the sharps containers;</li> <li>5. <b>Section III. C</b> - Check YES for "Additional Information" and indicate when Fluid Resistant Lab Coat/Gown and Safety Goggles are used;</li> <li>6. <b>Section V</b> - Check YES for "Additional Information" and describe when the different disinfectants are used.</li> </ol> <p><b>Form B – Microbial/Infectious Agents</b></p> <ol style="list-style-type: none"> <li>7. <b>Agents #1 and #2</b> - Indicate the institution for Dr. Way;</li> <li>8. <b>Agents # 1 and #2 - Agent's Characteristics - last sentence</b> - "bleed" should read "bleach";</li> <li>9. <b>Agents #1, #2 and #3 - Use <i>in vitro</i></b> - If agents are propagated/grown in the lab, check YES and state that they are;</li> <li>10. <b>Agent #3 - Agent's Characteristics</b> – Replace "severe cause" with "severe cases" and describe the PR8 strain;</li> </ol> <p><b>Form C – Human and NHP Derived Materials:</b></p> <ol style="list-style-type: none"> <li>11. <b>Form C - Section I - Table - Blood, serum, plasma</b> - change to "who are experiencing" and in "Description &amp; Source", -indicate from where the human materials listed are obtained.</li> <li>12. <b>Section II. A</b> - Change "collected <u>an</u>" to "collected <u>and</u>".</li> </ol> <p><b>Form D – Biohazard in Animals:</b></p> <ol style="list-style-type: none"> <li>13. <b>Section II</b> - Animals receiving bacteria (i.e. <i>L. monocytogenes</i>) should never be housed in LAMS standard area. Uncheck "standard housing" box;</li> <li>14. <b>Section III. A</b> - Describe the activities which might lead to potential exposure (e.g. handling/administration, needle stick);</li> <li>15. <b>Section III. C</b> - Check YES for "Additional Information" and list types of sharps that are disposed of in the sharps containers;</li> <li>16. <b>Section III. C</b> - If your animal procedures are performed exclusively in LAMS, uncheck the box for "bedding dump stations" since they do not have this type of equipment.</li> </ol>			
<b>Motion</b>	Approve upon modifications addressing outlined issues.			
<b>Voting Result &amp; Dual Use</b>	YES: 11	NO: 0	Abstained: 0	Dual Use? No

**A. Secondary Protocols (2 protocols)**

IBC Protocol Number	PI	Type of Submission	Biosafety Level	IBC Items
1. 25-10-20-02	Waters	Renewal	BSL2	<p><b><i>in vitro:</i></b> HDM (established cells), Lentiviral vector, <i>Escherichia coli</i> (RG1)</p> <p><b><i>in vivo:</i></b> Mouse transduced cells (lentivirus)</p>
<b>IBC Requests:</b>		<ol style="list-style-type: none"> <li>1. Lab staff need to complete their BBP training;</li> </ol> <p><b>Main Form – General Safety:</b></p> <ol style="list-style-type: none"> <li>2. <b>Section I. B</b> - If Secondary Contact does not have an office phone, enter "N/A";</li> <li>3. <b>Section III. B</b> - In Additional Information section, change "scalpal" to "scalpel" and indicate what scalpel safety device(s) is used.</li> </ol> <p><b>Form D – Biohazard in Animals:</b></p> <ol style="list-style-type: none"> <li>4. <b>Section I</b> - Provide your IACUC protocol number.</li> </ol>		
<b>Motion</b>	Approve upon modifications addressing outlined issues.			
<b>Voting Result &amp;</b>	YES: 10	NO: 0	Abstained: 0	Dual Use? No

Dual Use	One member did not vote			
----------	-------------------------	--	--	--

IBC Protocol Number	PI	Type of Submission	Biosafety Level	IBC Items
2. 25-11-19-01	Norton	Renewal	BSL2	<i>in vitro</i> : HDM (saliva, skin swab)
IBC Requests:	<b>Main Form – General Safety:</b> 1. <b>Section III. C</b> - Check YES for "Additional Information" and indicate when Safety Goggles and Face Shield are used.			
Motion	Approve upon modifications addressing outlined issues.			
Voting Result & Dual Use	YES: 11	NO: 0	Abstained: 0	Dual Use? No

#### V. Other New Business

The next IBC meeting falls on New Year's Day (01/01/26); therefore, an email will be sent to members to reschedule it for January 8, 2026.

#### VI. Protocol Updates October 29<sup>th</sup> to November 26<sup>th</sup> - 13 protocols

1. IBC# 25-02-13-01 - PI: Wang - Personnel and PI Reassignment
2. IBC# 23-10-19-02 - PI: Madan - Secondary Contact and Personnel
3. IBC# 24-01-20-02 - PI: Scaglioni - Personnel
4. IBC# 24-06-18-02 - PI: Hertlein - Personnel
5. IBC# 24-06-18-02 - PI: Thompson T - Personnel
6. IBC# 24-03-06-01 - PI: Luo - Personnel, Location
7. IBC# 24-03-08-02 - PI: Hyacinth - Personnel
8. IBC# 22-11-17-01 - PI: Kotagiri - Personnel
9. IBC# 25-07-08-01 - PI: Brewer - Secondary Contact and Personnel
10. IBC# 25-07-08-01 - PI: Apewokin - Secondary Contact and Personnel
11. IBC# 25-05-23-01 - PI: Lewis - Personnel
12. IBC# 25-10-20-03 - PI: Li - Location
13. IBC# 24-01-02-01 - PI: Waltz - Personnel

#### VI. Reports

- A. IBC/BSOf (M. Espinola)
  - NIH/OSP is having listening sessions related to modernization and strengthening oversight for biosafety, designated for each region.
    - There is a listening session for region 3 (Ohio) on January 15<sup>th</sup>, 2026.
    - M. Espinola will share the link for registration. Committee members can register to voice their opinion.

#### VII. Educational Materials/Updates

- A. [FDA Warning](#). U.S. Food and Drug Administration, November 2025.
- B. [RFK Jr. says the Trump administration is following 'gold standard' science. Here's what to know](#) PBS News - Health, November 2025

K. Burns adjourned the meeting at 12:22 p.m.